Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
43 Cards in this Set
- Front
- Back
|
Cervical dilation at time of transition from latent to active labor
|
3-4 cm
|
|
|
Normal range of beats/min (bpm) for fetal heart rate
|
120-160 bpm
|
|
|
Gestational weeks for preterm delivery
|
20-37 weeks
|
|
|
Percentage of all US deliveries affected by preterm birth (PTB)
|
10-12%
|
|
|
Negative predictive value of fetal fibronectin for preterm delivery
|
99.7%
|
|
|
Dose of folic acid in low risk patients
|
0.4 mg
|
|
|
Dose of folic acid in high risk patients
|
4 mg
|
|
|
Gestational weeks to perform medical termination
|
<49 days from LMP
|
|
|
% of chromosomal abnormalities in first trimester spontaneous abortion
|
50-75%
|
|
|
Threshold for bhcg level at which one should see intrauterine pregnancy
transvaginal ultrasound |
1600 mIU/ml
|
|
|
Gestational weeks to perform CVS
|
10-12 weeks
|
|
|
Risk of pregnancy loss with CVS
|
1/200
|
|
|
Gestational weeks to perform First Trimester Screening
|
11-13 6/7 weeks
|
|
|
Gestational weeks to perform amniocentesis
|
14-20 weeks
|
|
|
Loss rate for amniocentesis
|
1/400
|
|
|
Gestational weeks to perform second trimester (Quad) screening
|
15-20 weeks
|
|
|
Detection Rate for Down Syndrome using Quad Serum screening
|
70%
|
|
|
Increase in red blood cell mass during pregnancy
|
25-40%
|
|
|
Increase in plasma volume during pregnancy
|
50-100%
|
|
|
Increase in cardiac output in pregnancy
|
43%
|
|
|
Percentage of all pregnancies which are unintended
|
57%
|
|
|
Percentage of all couples achieving pregnancy in their first year of trying
|
85%
|
|
|
Risk of pregnancy per act of intercourse midcycle
|
17-30%
|
|
|
Failure rate of oral contraceptives with perfect to typical use
|
0.3-8%
|
|
|
Failure rate of condoms with perfect to typical use
|
2-15%
|
|
|
Failure rate of tubal ligation (range because of different techniques)
|
0.8-3.7%
|
|
|
Failure rate of Mirena IUD
|
0.1%
|
|
|
Duration for FDA approved MIrena IUD use
|
5 years
|
|
|
Duration for FDA approved Copper IUD use
|
10 years
|
|
|
Typical number of days in the luteal phase
|
14
|
|
|
Normal menstrual cycle duration
|
2-7 days
|
|
|
Normal menstrual cycle interval
|
24-35 days
|
|
|
Mean number of days in human menstrual cycle interval
|
28 days
|
|
|
Average age of menarche
|
12.5 years
|
|
|
Percentage of married couples who are satisfied with their sex lives
|
87%
|
|
|
Percentage of female adolescents in the US having at least one
of the most common STIs |
26%
|
|
|
Percentage of high school students who have ever had intercourse
|
47.8%
|
|
|
Risk of endometrial carcinoma in patients with hyperplasia without atypia
|
1-3%
|
|
|
Risk of endometrial carcinoma in patient with hyperplasia with atypia
|
8-29%
|
|
|
Percent of dysfunctional uterine bleeding caused by anovulation
|
90%
|
|
|
Decrease in menorrhagia in the ovulatory patient with NSAIDs
|
20%
|
|
|
Decrease in menorrhagia in the ovulatory patient with OCP’s
|
40%
|
|
|
Decrease in menorrhagia in the ovulatory patient with the Mirena
|
75-95%
|
